Through the looking glass An angioscopic view of the effect of statin therapyon coronary artery plaques**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Tawakol, Ahmed & Muller, James
EDITORIAL COMMENT
Through the Looking Glass
An Angioscopic View
of the Effect of Statin Therapy
on Coronary Artery Plaques*
Ahmed Tawakol, MD,†‡
James Muller, MD, FACC†‡
Boston, Massachusetts
Although there is no doubt that statins represent a marvel-
ous advance in the prevention of cardiovascular disease, two
observations indicate that the mechanisms of their beneficial
effects are not yet fully understood. First, although it is well
documented that statin therapy reduces death and acute
myocardial infarction (MI) by more than 25%, angiographic
studies have revealed that this benefit occurs with only a
minor improvement in coronary artery stenosis (1). Second,
whereas the lipid-lowering action of statins appears to
account for much of their beneficial effect, in some studies,
benefits have occurred that appear to be independent of
lipid levels (2,3). The angioscopic findings provided by
Takano et al. (4) in this issue of the Journal shine new light
on the theories advanced to explain these paradoxes.
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The discrepancy between the substantial clinical benefit
and persistent luminal stenosis has been attributed to
“stabilization” of plaques (5) presumed to be vulnerable to
disruption and thrombosis. However, there has been no
reliable method to test this hypothesis in patients. The
second discrepancy, the lack of a relation between the
degree of lipid lowering and the benefits observed in a
subset of studies, has been ascribed to positive actions of
statins other than lipid-lowering. These “pleiotropic” ef-
fects, which might prevent cardiac events, include the ability
to reduce inflammation, metalloproteinase activity, endo-
thelial dysfunction, plaque thrombogenicity, and systemic
coagulation tendency (6). Each of these actions is theoret-
ically capable of blocking the complex pathophysiologic
process leading from plaque formation to plaque disruption,
and ultimately to cardiac events.
PATHOPHYSIOLOGY OF CORONARY EVENTS
Established facts. Many steps in the transition from
asymptomatic atherosclerosis to the cardiac events of unsta-
ble angina, nonfatal MI, and sudden cardiac death are well
understood. There is general agreement that these acute
coronary syndromes most often result from disruption of a
plaque that did not cause significant stenosis before the
event. Such plaques, with a high risk of disruption, have
been termed “vulnerable” plaques (7).
Although only limited prospective data are available, retro-
spective data indicate that the most common histologic type of
vulnerable plaque is a lesion that has a large lipid pool, a thin
cap, and an inflammatory infiltrate (8). Such thin-capped
fibroatheromas have been referred to as TCFAs (9). The
presence of proteolytic enzymes and positive remodeling has
also been associated with vulnerability (10,11).
There are data to suggest that plaque disruption is often
triggered by activities of patients, but it may also result from
processes within the plaque (12). In many cases, the
disruption produces only a minor mural thrombosis, which
then organizes without causing ischemia or producing
symptoms. Numerous factors may affect the likelihood that
a plaque’s rupture will lead to unstable angina or a more
serious cardiac event. If the thrombotic stimulus of the
disrupted plaque is high, the rheology favorable, and the
systemic clotting tendency increased, the thrombus may
become occlusive (13). If the lesion is located in a large
vessel without sufficient collaterals, and if increased vaso-
constrictor tone is present, the occlusion may produce
myocardial ischemia. Limited and transient ischemia may
produce only unstable angina, whereas more severe and
permanent ischemia leads to MI. Ischemia may produce
sudden cardiac death directly by causing an arrhythmia, or
indirectly, through the results of a MI. Sudden death may
be more likely if the myocardium is vulnerable to arrhyth-
mias.
Areas of uncertainty. Despite this considerable under-
standing of pathophysiology, questions remain about pro-
cesses related to the plaque, ischemia, and cardiac events of
infarction and sudden death.
The distribution of vulnerability to disruption within the
coronary arteries is not known. Because atherosclerosis is a
systemic disease, and systemic markers of inflammation
predict coronary events (14), it can be argued that vulnera-
bility is a diffuse process that will not benefit from local
diagnosis or local therapy. Alternatively, because patients gen-
erally experience difficulty at only a single spot in an artery, it
can be argued that vulnerability is, in many cases, focal. Recent
data on the presence of multiple disrupted plaques in some
patients with an acute coronary syndrome suggest that in these
cases, vulnerability was at least multifocal (15).
If it is assumed that vulnerability is focal or even multi-
focal, then it is of value to further characterize the tissue
types that lead to vulnerability. The inflamed TCFA is
generally considered to be the most common type of
vulnerable plaque and other, less common subtypes have
been identified. As the histologic subtypes are characterized
further through autopsy studies, it will be necessary to
determine if such sites can be identified in advance of their
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rupture. If so, this would make it possible to create a
much-needed index of vulnerability for plaque disruption.
The vulnerable patient. Although it is certain, on the basis
of autopsy findings, that plaque disruption does not always
lead to symptoms (16), the frequency of asymptomatic
plaque disruption in living patients is not known. For each
disruption that leads to symptoms, it has been estimated
that as many as 10 asymptomatic disruptions occur. Im-
proved knowledge of the factors leading from a vulnerable
plaque to disruption, and then to unstable angina, MI, and
sudden cardiac death would enhance efforts to develop an
index of vulnerability for a cardiac event—a means to identify
the vulnerable patient. Such an index will likely prove to be
more useful than a plaque disruption index as a guide for
clinical interventions.
CONTRIBUTION OF ANGIOSCOPY
Coronary angioscopy is an excellent research tool with
which to approach the unanswered questions regarding
plaque vulnerability, plaque disruption, and the effect of
treatment in living patients. In contrast to angiography,
which provides little information beyond the degree of
stenosis a coronary plaque is causing, angioscopy provides
an excellent view of the color and luminal surface features of
plaques. Autopsy correlation studies have established that
fibrotic plaques are white, plaques with lipid pools are
yellow, and that more intense shades of yellow are associated
with thinner caps. Angioscopy is an extremely sensitive
detector of thrombus and intimal surface irregularities,
which makes it an excellent method for identification of
disrupted plaques. Several studies, which require confirma-
tion, suggest that yellow plaque color predicts plaque
disruption and clinical events (17–20). The major limitation
of the technique is that it requires coronary artery occlusion
and removal of blood from the field of view.
The study by Takano et al. (4) reported in this issue of the
Journal utilizes this powerful research tool to assess possible
coronary plaque stabilization by statin therapy. The authors
report that 12 months of therapy with atorvastatin reduced
the yellow score of plaques and reduced signs of plaque
disruption compared with the results observed in a nonran-
domized comparison group. The decrease in plaque color
correlated with the decrease in low-density lipoprotein
(LDL), whereas there was no correlation between the
decrease in disrupted score and the decrease in LDL.
Several methodologic issues need to be considered before
interpreting the results of this study. The study was not
randomized or fully blinded, and the end point, the intensity
of color by visual inspection, is subjective. The lack of
random assignment to statin therapy raises questions about
the comparability of the groups and similarity of end point
acquisition methods. Although the groups are matched for
several variables, the study results may be confounded by
uneven distribution of additional unidentified baseline vari-
ables related to the study outcomes. Further, although the
image analysis was blinded, biased image acquisition could
have occurred because the intensity of the light was adjusted
for each patient. If a stronger light were used at follow-up in
the atorvastatin cases, the plaques might incorrectly appear
to be whiter in the treated group (21,22).
For the sake of discussion, let us assume that these
limitations did not compromise the validity of the study,
and that similar results would be obtained in a confirmatory
study. The decrease in the yellow score with atorvastatin
therapy and the direct correlation of that decrease with the
degree of LDL lowering presumably reflect a decrease in the
lipid content of plaques and/or an increase in thickness of
the caps overlying lipid pools—changes that would be
expected to stabilize the plaque. This beneficial histologic
change has also been suggested in a trial of statin therapy in
which measurements were made with intravascular ultra-
sound. In the statin-treated group, the echogenicity of the
plaques increased after lipid lowering, suggesting the con-
version of lipid-rich plaques to a more stable fibrous
composition (23).
Histologic documentation of such changes has been
obtained in an animal model, in which nonhuman primates
were transferred from an atherogenic to a nonatherogenic
diet. Although similar histologic data from coronary pa-
tients are not available, changes with therapy have been
examined in carotid artery endarterectomy specimens. Prav-
astatin therapy enhanced the collagen content and decreased
the lipid content of carotid plaques. In aggregate, these
studies and the findings of the present study make it quite
likely that atorvastatin therapy decreased the lipid content
and/or increased cap thickness in these patients, changes
expected to stabilize plaques.
Support for the conclusion that the plaques were stabi-
lized is provided by the second observation of Takano et al.
(4) that, in the atorvastatin-treated group, the disruption
score (an index of thrombosis and/or intimal disruption)
was also decreased. In contrast to the findings for lipid-
related yellow score, this change was not correlated with the
change in LDL level.
It may be that the lack of correlation is due to the
relatively small sample size. However, it is also possible that
the atorvastatin therapy prevented plaque disruption by
other effects in addition to LDL lowering. The pleiotropic
effects of statin may well be additional contributors to
enhanced cap integrity and reduced thrombosis. This find-
ing is in accord with clinical studies in which the decrease in
events produced by statin therapy is not consistently corre-
lated with the change in LDL levels.
Both the decrease in yellow score and the decrease in
disruption score are signs of plaque stabilization by a statin
that could explain the apparent paradox discussed earlier,
that the clinical benefits of statin therapy exceed their effects
on coronary stenosis (1).
FUTURE USE OF ANGIOSCOPY
This study clearly demonstrates the ability of angioscopy, as
a research tool, to contribute to our understanding of events
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within the coronary arteries of living patients. As was this
study, the majority of the valuable angioscopy studies have
been performed in Japan. Perhaps these intriguing results
will increase the use of angioscopy in the U.S. and other
countries where it is an underutilized research tool.
In the near term, it would be extremely useful if an
attempt could be made to replicate the findings of Takano
et al. (4) in a randomized trial. Studies in larger numbers of
patients will be needed to confirm the reported findings of
other studies indicating that yellow plaques are more likely
to cause clinical events than are white plaques. Testing of
this linkage would be an important contribution to the
debate as to whether there are discrete locations in a
coronary artery, which can be identified prospectively, that
have an increased likelihood of causing an event.
Despite its utility as a research tool for use in specialized
centers, angioscopy is not well suited for use in multicenter
studies, and certainly is not a desirable tool for clinical use,
because it requires a blood-free field. However, it may be
possible to use angioscopy as a standard for validation of
other intravascular techniques to detect vulnerable plaque
(such as thermography) (24), that do not require coronary
occlusion
These less demanding techniques, perhaps together with
angioscopy itself, should be compared to determine the best
method to identify foci of vulnerability to disruption. If such
foci exist, and can be detected, the device could then be used
to select high-risk patients for enrollment in trials of
therapy. In a trial of local treatment, which might be
possible with drug-eluting stents, photodynamic agents, or
other measures, the device would indicate the site in need of
therapy. In a trial of systemic treatment, perhaps with
extreme lipid lowering, the method could be used to obtain
a follow-up measurement, as was done in the present study,
to evaluate the effect of therapy on an index of vulnerability
that can be attained with smaller numbers of patients than
would be required for a clinical end point.
Although the potential benefits of vulnerable plaque
detection and treatment are massive, at present, there are
insufficient data to recommend routine clinical attempts to
detect or treat such lesions. Clinical studies in large numbers
of patients must first demonstrate that detection and treat-
ment of vulnerable plaques reduces cardiac events. Detec-
tion and treatment must also be shown to be cost-effective.
Angioscopy may contribute to such trials, or at least to the
development of less complex detection techniques for use in
such trials, as indicated by the important findings of Takano
et al. (4).
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